GlaxoSmithKline PLC Director/PDMR Shareholding (4722V)
April 14 2021 - 6:58AM
UK Regulatory
TIDMGSK
RNS Number : 4722V
GlaxoSmithKline PLC
14 April 2021
GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Ms E Walmsley
==== ====================================== ====================================================
b) Position/status Chief Executive Officer
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 April 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP13.2160 796
=========================================== ========================== ======================
GBP13.2160 1,190
========================== ======================
GBP13.2160 957
========================== ======================
d) Aggregated information 2,943
====
Aggregated volume GBP13.2160
Price
=========================================== ====================================================
e) Date of the transaction 2021-04-12
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Dr H Barron
==== ======================================= ===================================================
b) Position/status Chief Scientific Officer and President,
R&D
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================= ===================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 8 April 2021 on ADSs held
in the Company's Deferred Annual Bonus
Plan
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= ======================
$ 36.4600 420
============================================ ========================= ======================
$ 36.4600 707
========================= ======================
$ 36.4600 555
========================= ======================
d) Aggregated information 1,682
====
Aggregated volume $36.4600
Price
============================================ ===================================================
e) Date of the transaction 2021-04-12
==== ======================================= ===================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ===========================================================================================
a) Name Mr R Connor
==== ===================================== ====================================================
b) Position/status President, Global Vaccines
==== ===================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ===========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ===========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ===================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 April 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ===================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== =========================== =====================
GBP 13.2160 175
========================================== =========================== =====================
GBP 13.2160 312
=========================== =====================
GBP 13.2160 302
=========================== =====================
d) Aggregated information 789
====
Aggregated volume GBP 13.2160
Price
========================================== ====================================================
e) Date of the transaction 2021-04-12
==== ===================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ===================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ===========================================================================================
a) Name Ms D Conrad
==== ===================================== ====================================================
b) Position/status SVP Human Resources
==== ===================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ===========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ===========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ===================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 April 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ===================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== =========================== =====================
GBP 13.2160 115
========================================== =========================== =====================
GBP 13.2160 124
=========================== =====================
d) Aggregated information 239
====
Aggregated volume GBP13.2160
Price
========================================== ====================================================
e) Date of the transaction 2021-04-12
==== ===================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ===================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr J Ford
==== ====================================== ====================================================
b) Position/status Senior Vice President and General Counsel
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 April 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP13.2160 139
=========================================== ========================== ======================
GBP13.2160 177
========================== ======================
d) Aggregated information 316
====
Aggregated volume GBP13.2160
Price
=========================================== ====================================================
e) Date of the transaction 2021-04-12
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =============================================================================================
a) Name Mr J Ford
==== ======================================= ====================================================
b) Position/status Senior Vice President and General Counsel
==== ======================================= ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================= ====================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 8 April 2021 on ADSs held
in the Company's Deferred Annual Bonus
Plan
==== ======================================= ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= ======================
$ 36.4600 60
========================= ======================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
======================================== ========================================================
e) Date of the transaction 2021-04-12
==== ======================================= ====================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================= ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ===========================================================================================
a) Name Mr N Hirons
==== ===================================== ====================================================
b) Position/status SVP, Global Ethics & Compliance
==== ===================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ===========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ===========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ===================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 April 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ===================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== =========================== =====================
GBP 13.2160 69
========================================== =========================== =====================
GBP 13.2160 130
=========================== =====================
GBP 13.2160 93
=========================== =====================
d) Aggregated information 292
====
Aggregated volume GBP 13.2160
Price
========================================== ====================================================
e) Date of the transaction 2021-04-12
==== ===================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ===================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ===========================================================================================
a) Name Ms S Jackson
==== ===================================== ====================================================
b) Position/status SVP, Global Communications & CEO Office
==== ===================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ===========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ===========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ===================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 April 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ===================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== =========================== =====================
GBP 13.2160 70
========================================== =========================== =====================
GBP 13.2160 75
=========================== =====================
d) Aggregated information 145
====
Aggregated volume GBP13.2160
Price
========================================== ====================================================
e) Date of the transaction 2021-04-12
==== ===================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ===================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ===========================================================================================
a) Name Mr I Mackay
==== ===================================== ====================================================
b) Position/status Chief Financial Officer
==== ===================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ===========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ===========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ===================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 April 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ===================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== =========================== =====================
GBP 13.2160 552
========================================== =========================== =====================
GBP13.2160 646
=========================== =====================
d) Aggregated information 1,198
====
Aggregated volume GBP13.2160
Price
========================================== ====================================================
e) Date of the transaction 2021-04-12
==== ===================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ===================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr B McNamara
==== ======================================= ===================================================
b) Position/status CEO, GSK Consumer Healthcare
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================= ===================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 8 April 2021 on ADSs held
in the Company's Deferred Annual Bonus
Plan
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== --------------------------------------- ========================= ======================
$ 36.4600 128
-------------------------------------------- ========================= ======================
$ 36.4600 119
========================= ======================
$ 36.4600 102
------------------------- ----------------------
d) Aggregated information 349
====
Aggregated volume $ 36.4600
Price
============================================ ===================================================
e) Date of the transaction 2021-04-12
==== ======================================= ===================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr L Miels
==== ====================================== ====================================================
b) Position/status President, Global Pharmaceuticals
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 April 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP13.2160 215
=========================================== ========================== ======================
GBP13.2160 332
========================== ======================
GBP13.2160 289
========================== ======================
d) Aggregated information 836
====
Aggregated volume GBP13.2160
Price
=========================================== ====================================================
e) Date of the transaction 2021-04-12
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr D Redfern
==== ====================================== ====================================================
b) Position/status Chief Strategy Officer
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 April 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP13.2160 169
=========================================== ========================== ======================
GBP13.2160 295
========================== ======================
GBP13.2160 212
========================== ======================
d) Aggregated information 676
====
Aggregated volume GBP13.2160
Price
=========================================== ====================================================
e) Date of the transaction 2021-04-12
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr R Simard
==== ====================================== ====================================================
b) Position/status President, Pharmaceuticals Supply Chain
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 April 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP13.2160 127
=========================================== ========================== ======================
GBP13.2160 106
========================== ======================
GBP13.2160 150
========================== ======================
d) Aggregated information 383
====
Aggregated volume GBP13.2160
Price
=========================================== ====================================================
e) Date of the transaction 2021-04-12
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Ms K Terrell
==== ======================================= ===================================================
b) Position/status Chief Digital & Technology Officer
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================= ===================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 8 April 2021 on ADSs held
in the Company's Deferred Annual Bonus
Plan
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= ======================
$ 36.4600 81
============================================ ========================= ======================
$ 36.4600 150
========================= ======================
$ 36.4600 103
========================= ======================
d) Aggregated information 334
====
Aggregated volume $ 36.4600
Price
============================================ ===================================================
e) Date of the transaction 2021-04-12
==== ======================================= ===================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr P Thomson
==== ====================================== ====================================================
b) Position/status President, Global Affairs
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 April 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP13.2160 99
=========================================== ========================== ======================
GBP13.2160 172
========================== ======================
GBP13.2160 122
========================== ======================
d) Aggregated information 393
====
Aggregated volume GBP13.2160
Price
=========================================== ====================================================
e) Date of the transaction 2021-04-12
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Ms D Waterhouse
==== ====================================== ======================================================
b) Position/status Chief Executive Officer of ViiV Healthcare
==== ====================================== ======================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ======================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ======================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ======================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ======================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 April 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ======================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== =========================== ======================
GBP13.2160 204
======================================================================= ======================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
==================================================================== =============================
e) Date of the transaction 2021-04-12
==== ====================================== ======================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ======================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBZLFFFZLEBBQ
(END) Dow Jones Newswires
April 14, 2021 06:58 ET (10:58 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
